# Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

> **NCT00400400** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 400 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Enteric-coated mycophenolate sodium (EC-MPS)
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Placebo to mycophenolate sodium
- **DRUG:** Placebo to mycophenolate mofetil

## Key facts

- **NCT ID:** NCT00400400
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2011-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400400, "Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00400400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*